{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:58Z","timestamp":1790792638898,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Berit Linnea and Ragnar Bakken Foundation"},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40263-023-00985-x","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T05:09:00Z","timestamp":1675314540000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Jan","family":"Lycke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Farman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-364X","authenticated-orcid":false,"given":"Anna","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"issue":"9","key":"985_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/ni1507","volume":"8","author":"HF McFarland","year":"2007","unstructured":"McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8(9):913\u20139.","journal-title":"Nat Immunol"},{"issue":"5","key":"985_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278\u201385.","journal-title":"N Engl J Med"},{"issue":"Pt 5","key":"985_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","volume":"132","author":"JM Frischer","year":"2009","unstructured":"Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175\u201389.","journal-title":"Brain"},{"issue":"Pt 2","key":"985_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/brain\/awq350","volume":"134","author":"L Lovato","year":"2011","unstructured":"Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134(Pt 2):534\u201341.","journal-title":"Brain"},{"key":"985_CR5","unstructured":"Commission E. Public Health\u2014Union Register of medicinal products\u2014Aubagio. 2022. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h838.htm. Cited 8 Dec 2022."},{"key":"985_CR6","unstructured":"Genzyme. Aubagio US product information. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aubagio-epar-product-information_en.pdf. Cited 8 Dec 2022."},{"issue":"3","key":"985_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247\u201356.","journal-title":"Lancet Neurol"},{"issue":"14","key":"985_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O'Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293\u2013303.","journal-title":"N Engl J Med"},{"issue":"10","key":"985_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","volume":"13","author":"AE Miller","year":"2014","unstructured":"Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(10):977\u201386.","journal-title":"Lancet Neurol"},{"issue":"6","key":"985_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","volume":"66","author":"PW O'Connor","year":"2006","unstructured":"O\u2019Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894\u2013900.","journal-title":"Neurology"},{"key":"985_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","volume":"5","author":"G Comi","year":"2016","unstructured":"Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016;5:97\u2013104.","journal-title":"Mult Scler Relat Disord."},{"issue":"Pt 2","key":"985_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1042\/bj3360299","volume":"336","author":"JM Bruneau","year":"1998","unstructured":"Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J. 1998;336(Pt 2):299\u2013303.","journal-title":"Biochem J"},{"issue":"2","key":"985_CR13","first-page":"1043","volume":"275","author":"HM Cherwinski","year":"1995","unstructured":"Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995;275(2):1043\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"34","key":"985_CR14","doi-asserted-by":"publisher","first-page":"21682","DOI":"10.1074\/jbc.273.34.21682","volume":"273","author":"K Ruckemann","year":"1998","unstructured":"Ruckemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998;273(34):21682\u201391.","journal-title":"J Biol Chem"},{"issue":"6","key":"985_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","volume":"41","author":"B Rozman","year":"2002","unstructured":"Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002;41(6):421\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"985_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jpba.2011.01.034","volume":"55","author":"H Rakhila","year":"2011","unstructured":"Rakhila H, Rozek T, Hopkins A, Proudman S, Cleland L, James M, et al. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS\/MS. J Pharm Biomed Anal. 2011;55(2):325\u201331.","journal-title":"J Pharm Biomed Anal"},{"key":"985_CR17","doi-asserted-by":"crossref","unstructured":"Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric level. Eur J Clin Pharmacol. 2011;67(2):129\u201334","DOI":"10.1007\/s00228-010-0916-0"},{"key":"985_CR18","doi-asserted-by":"crossref","unstructured":"Thiele Nee Schrewe L, Guse K, Tietz S, Remlinger J, Demir S, Pedreiturria X, et al. Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis. J Neuroinflamm. 2020;17(1):9.","DOI":"10.1186\/s12974-019-1677-z"},{"key":"985_CR19","unstructured":"Kaplan JSCST. Biodistribution of teriflunomide in na\u00efve rats vs rats with experimental autoimmune encephalomyelitis. In: 31st congress of the European Committee for treatment and research in multiple sclerosis. Barcelona, Spain; 2015."},{"issue":"1","key":"985_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1432-1033.1996.0292h.x","volume":"240","author":"W Knecht","year":"1996","unstructured":"Knecht W, Bergjohann U, Gonski S, Kirschbaum B, Loffler M. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur J Biochem. 1996;240(1):292\u2013301.","journal-title":"Eur J Biochem"},{"issue":"11","key":"985_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology"},{"issue":"22","key":"985_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914\u201322.","journal-title":"Neurology"},{"key":"985_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102463","volume":"46","author":"L Novakova","year":"2020","unstructured":"Novakova L, Axelsson M, Malmestrom C, Zetterberg H, Blennow K, Svenningsson A, et al. NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. Mult Scler Relat Disord. 2020;46: 102463.","journal-title":"Mult Scler Relat Disord."},{"issue":"5","key":"985_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/00365517709091497","volume":"37","author":"H Link","year":"1977","unstructured":"Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Investig. 1977;37(5):391\u20136.","journal-title":"Scand J Clin Lab Investig."},{"issue":"6","key":"985_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"985_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/1872312813666190311125652","volume":"13","author":"L Huang","year":"2019","unstructured":"Huang L, Wells MC, Zhao Z. A practical perspective on the evaluation of small molecule CNS penetration in drug discovery. Drug Metab Lett. 2019;13(2):78\u201394.","journal-title":"Drug Metab Lett"},{"issue":"7","key":"985_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/ard.2007.086264","volume":"68","author":"E Kis","year":"2009","unstructured":"Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009;68(7):1201\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"985_CR28","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230\u20137.","journal-title":"Neurology"},{"issue":"6","key":"985_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857\u201370.","journal-title":"Ann Neurol"},{"issue":"11","key":"985_CR30","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","volume":"94","author":"B Delcoigne","year":"2020","unstructured":"Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020;94(11):e1201\u201312.","journal-title":"Neurology"},{"issue":"13","key":"985_CR31","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1177\/13524585221108080","volume":"28","author":"M Johnsson","year":"2022","unstructured":"Johnsson M, Farman HH, Blennow K, Zetterberg H, Malmestrom C, Axelsson M, et al. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Mult Scler. 2022;28(13):2070\u201380.","journal-title":"Mult Scler"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-00985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-00985-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-00985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T12:19:08Z","timestamp":1676290748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-00985-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-00985-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"10 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was an investigater-sponsored study funded by Sanofi and supported by grants from Berit Linnea and Ragnar Bakken Foundation.\u00a0Open access funding was provided by University of Gothenburg.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JL has received lecture honoraria from Biogen, BMS, Celgene, Janssen, Merck, Novartis, Sanofi, Roche and Alexion; has served on scientific advisory boards for Biogen, BMS, Merck, Novartis, Sanofi, Roche and Alexion; serves on the editorial board of the Acta Neurologica Scandinavica; and has received unconditional research grants from Biogen and Novartis. HF and AN: no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"On request, through email contact, original data can be provided by the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study was approved by the regional ethical review board of Gothenburg, Sweden (diary number 773-17) and registered in ClinicalTrials.gov (Identifier: NCT04129736 ( NCT04129736)). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients participated voluntary in this study and informed consent was obtained from all subjects.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JL conceptualised and planned the study, collected data, wrote and contributed intellectually to the manuscript. HF analysed biomarkers in plasma and cerebrospinal fluid, reviewed and contributed intellectually to the manuscript. AN collected the data, performed the analytic calculations and compiled the figures, reviewed and contributed intellectually to the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}